1	Development and Validation of a Diagnostic
2	Prediction Rule for Osteopenia
3	
4	Thammabhorn Janwittayanuchit ¹
5	Naritsaret Kaewboonlert ^{2,*}
6	Pornthep Tangkanjanavelukul ²
7	Kitirat Phattaramarut ²
8	Pattama Thongdee ²
9	
10	1 Suranaree University of Technology Hospital, Nakhon Ratchasima 30000, Thailand
11 12	2 Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand
13	
14 15 16	* Corresponding author: School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand. Tel: +66 4422 3956, E-mail: naritcvt@gmail.com
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	

27 Abstract

28 Objectives

- 29 To triage patients with a high likelihood of osteopenia before referring them for a standard bone
- 30 mass density test for diagnosis.

31 Introduction

Osteopenia defined by low bone mineral density, is a precursor for osteoporosis and is primarily associated with aging-linked natural bone loss in adulthood. The model and findings can be used to adopt an inclusive screening and swift treatment model that can work in most settings where resources are limited.

36 Methods

We developed a diagnostic prediction rule based on clinical characteristics. A retrospective cohort of 798 patients who were going to be diagnosed with osteopenia or osteoporosis, within January-September 2022. The multivariable logistic regression to assess potential predictors. The logistic coefficients were transformed as a risk-based scoring system. The internally validation was performed using a bootstrapping procedure.

42 Results

The model initially included seven predictors: sex, age, height, weight, body mass index, diabetes mellitus, and estimated glomerular filtration rate. However, after using backward elimination for model reduction, only three predictors—sex, age, and weight—were retained in the final model. The discrimination performance was assessed with the area under the receiver operating characteristic curve (AuROC); it was 0.779 (95%CI 0.74-0.82), and the calibration plot showed

48	good calibration. For internal validation, bootstrap resampling was utilized, yielding an AuROC of
49	0.768 (95% CI 0.73-0.81), indicating robust performance of the model.
50	Conclusions
51	This study developed and internally validated the Osteopenia Simple Scoring System. This clinical
52	risk score could be one of the important tools for diagnosing osteopenia and allocating resources
53	in resource-limited settings.
54	
55	Keywords
56	Osteopenia, Osteoporosis, Risk prediction, Diagnostic prediction rule, Clinical prediction
57	

58 Introduction

59 Osteopenia is a decrease in bone mineral density (BMD) below normal values for their 60 ages, is the initial stage of bone loss, which may progress to a more severe condition i.e. osteoporosis. However, that doesn't always lead to osteoporosis depending on many factors. The 61 62 primary cause of osteopenia is the natural bone loss that occurs gradually during adulthood. 63 Secondary causes supposed to accelerate bone loss include lifestyle factors[1] such as smoking. 64 certain underlying diseases, steroid usage, early menopausal woman, rheumatoid arthritis, and 65 some medications as well. Osteopenia is often a precursor to osteoporosis, which are now diagnosed by measuring bone mineral density using dual energy X-ray absorptiometry bone 66 scans.[2] The osteopenia, as defined by the World Health Organization (WHO) is a t-score 67 between -1 to -2.5, while values less than -2.5 are diagnostic for osteoporosis.[3, 4] Osteopenia 68

is not considered a disease while osteoporosis is. In the other hand, osteopenia is considered amarker for risk of fractures.[5]

The potential predictors of bone mass density in patients with fractures treated in hospitals were found that factors such as age, sex, smoking, history of adult wrist fractures, spinal deformities[6, 7], history of adult hip fractures, and osteoarthritis of the spine[8] significantly differed statistically between groups with normal bone mass density and those with bone mass density below -1 standard deviation. Low body mass index, low vitamin D level[9] and diabetes[10, 11], chronic kidney disease[12] are also associated with osteoporosis.

There has been increasing attention to the clinical predictive models of diagnostic screening models for the prediction of fracture risk in patients diagnosed with osteoporosis.[13-16] Clinical predictive models are commonly used in clinics for the purpose of disease diagnosis, outcome prediction, and evaluation of the clinical response.[17, 18] We used multivariable logistic regression to develop predictive models for possible use in the facilitation of early treatment and screening for osteopenia.

In countries with limited resources, access to a test for bone mass density would be farfetched. This research aims to help triage patients at high risk of having osteopenia before they are referred for a standard BMD test for diagnosis. This work could be extended to programs aimed to osteopenia or osteoporosis screening in the community.

87

88 Methods

89 Study design and setting

This diagnostic prediction research, utilizing a retrospective cohort design, was conducted at Suranaree University of Technology Hospital in Nakhon Ratchasima, located in the lower northeastern region of Thailand. Our university hospital conducts more than 2,000 bone mass density tests annually.

This study gathered demographic and laboratory data, including age, weight, height, body mass index, smoking status, early menopause, rheumatoid arthritis, diabetes mellitus, chronic kidney disease, serum creatinine, and estimated glomerular filtration rate levels from the electronic medical records of Suranaree University Technology Hospital. The data collection period spanned from January to September 2022. BMD was used in the analysis. Participants previously diagnosed with osteopenia or osteoporosis were excluded from the study.

100

101 **Confirmation of cases**

All patients included in this study underwent a BMD test on a single machine at the hospital's checkup center. In this study, osteopenia is defined as a T-score of less than -1, and osteoporosis is defined as a T-score of less than -2.5.

105

106 Statistical analysis and sample size calculations

107 Continuous variables were assessed for normality and presented as means and standard 108 deviations if normally distributed, or medians and interquartile ranges if not. Mean differences of 109 the variables between the two groups were compared by using an independent t-test, or rank-110 sum test based on the distribution of the data. Categorical data were expressed as frequencies 111 and percentages of the total in each group and compared between groups using either the exact 112 probability test or chi-square test where applicable. We assessed diagnostic performance and

113 potential prediction by univariable logistic regression, using crude odds ratios (OR) and their 114 corresponding area under the receiver operating characteristic curves (AuROC). Statistically significant two-sided p-values less than 0.05 were considered in applicable cases. All analyses 115 were done using Stata statistical software version 17. In the development of clinical prediction 116 117 rules based on methods described by Riley et al. [19], it was estimated that the minimum sample size for a multivariable prediction model with a binary outcome was required. This was estimated 118 119 from a model c-statistic of 0.8, six candidate predictors, and an assumed prevalence of 120 osteopenia from a preliminary study, standing at 46%, to get the minimum sample size of 382 121 cases with 176 events.

122

123 Model development and validation

All potential predictor variables necessary for diagnostic prediction of osteopenia in our routine practice were extracted from the hospital's electronic medical records. These included age, sex, height, weight, smoking status, serum creatinine levels, diabetes mellitus (with or without insulin use), hypertension, early menopause, chronic kidney disease, steroid use, and rheumatoid arthritis.

129 We identified potential predictors based on prior knowledge; about the biological process, 130 a review of the literature, and available prediction models. Subsequently, the exploratory analysis of significant predictors was done using a univariable logistic regression. We assessed the 131 significance of the predictors through the diagnostic odds ratio and the corresponding p-value. 132 133 Additionally, we assessed the area under the receiver operating characteristic curve (AuROC) for 134 each univariable logistic model. Any predictor variable showing an odds ratio >1.00, significant pvalue of <0.05, and higher AuROC than others was included in the model. Continuous potential 135 variables were categorized into ordinal following the preceding model and review of literature. 136

Therefore, in this respect, understanding the nature of the relationship between the dependentvariable and the outcome to determines the cut-off point.

The model to be used for the study is derived from the multivariable logistic regression 139 with a binary outcome. The factors that not contributing to the outcome were removed using the 140 141 backward elimination method. A total of four predictors got pruned from the model: height, body 142 mass index, diabetes mellitus, and estimated glomerular filtration rate. Diagnostic performance of the developed model was assessed using the reduced multivariable model by means of 143 calibration and discrimination. Calibration was assessed by the Hosmer-Lemeshow goodness-of-144 fit test, and a plot was applied to show both the model-estimated disease probabilities and 145 observed disease data. The discriminative ability of the model was graphically tested through a 146 147 distributional plot. It was reported with the area under the curve of the receiver operating characteristic. The internal validation was conducted using the bootstrapping procedure of 1000 148 149 replications.

150

151 Simplified score derivation

Each predictor in the multivariable model was assigned a specific score based on the logistic regression coefficients. The coefficient of each predictor was divided by the smallest coefficient and then rounded up to the nearest whole number. Utilizing a population-analogue approach, the positive predictive value (PPV) was calculated to demonstrate the predictive performance. Calibration and discrimination measurements were also conducted using the scorebased multivariable logistic model.

158

159 **Ethical considerations**

160 This research was conducted based on ethical standards of clinical research. According 161 to the Helsinki Declaration and began its activity only after it received approval and permission 162 from the Institutional Review Board of Suranaree University of Technology regarding the review of the research protocol. Retrospective data were extracted through data record forms. The 163 164 patients were treated by the routine hospital staff and were not affected by any research protocols, the informed consent was waived. The study adhered to the reporting guidelines outlined in the 165 166 Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis 167 (TRIPOD) statement. The study protocol received approval from the Institutional Review Board of Suranaree University of Technology, with approval number COA No.32/2567. 168

169

170 **Results**

171 **Participants**

A total of 798 participants were evaluated for osteopenia at the Suranaree University of 172 173 Technology check-up center from January to September 2022. After excluding 242 patients previously diagnosed with osteopenia or osteoporosis, the remaining 556 patients were divided 174 into two groups: 230 in the osteopenia group and 326 in the non-osteopenia group. The 175 prevalence of osteopenia and osteoporosis was 41.4% and 5.4%, respectively. Of these, 198 176 patients in the osteopenia group and 188 in the non-osteopenia group were female. The mean 177 178 age for the osteopenia group was 65.07±10.34 years, compared to 59.03±9.14 years for the nonosteopenia group. The average weight was 57.40±9.58 kg for osteopenia cases and 57.40±12.71 179 180 kg for non-osteopenia cases. Average heights were 155.22±7.50 cm for the osteopenia group 181 and 160.53±8.00 cm for the non-osteopenia group. The mean BMI was 24.68±14.44 kg/m² for 182 osteopenia cases and 25.64±4.02 kg/m² for non-osteopenia cases (Table 1). There were

significant differences in groups in terms of female gender, age, weight, height, BMI, and current
 underlying diseases, including diabetes mellitus, as well as in laboratory factors such as estimated
 glomerular filtration rate (eGFR) (p < 0.001). There were no significant differences in the serum
 creatinine, early menopause, rheumatoid arthritis, and smoking status.

187

188 Model development and internal validation

The following continuous variables were converted to ordinal variables: eGFR, body mass index, weight, age, and height. The cut points were determined based on information gathered from the literature and prior models. The model was developed using multivariable logistic regression, which demonstrated the relevant characteristics included in the regression for predicting osteopenia were female gender, age, height, weight, BMI, diabetes mellitus, and eGFR. These factors remained significant in the multivariable logistic regression analysis and were integrated into the full risk prediction model (Table 2).

The reduced model employed a backward elimination strategy. Multivariable logistic regression indicated that female gender, age, and weight, which were included in the final model, were found to be statistically significant. The scoring ranged from 1 to a maximum of 5 points, accumulating to a total of 13 points, summing up to 133. Ages over 70 years were assigned the highest scores (Table 3).

The calibration plot of the estimated risk of osteopenia compared to the actual risk showed acceptable calibration, with observed probabilities closely matching the expected probabilities and exhibiting minimum variation from the ideal (Figure 2). The Hosmer-Lemeshow goodness-offit statistic yielded a non-significant result for the outcome (p = 0.614), suggesting that the statistical fitness of the model was satisfactory, given that a p-value larger than 0.1 was regarded

indicative of a good fit. Area under the receiver operating characteristic curve (AuROC) was
 0.7792 (95% CI 0.74-0.82), showing a good performance in model discrimation (Figure 3).

The process of internal validation was conducted by utilizing a bootstrap resampling technique with 1000 repeats. Following the adjustment for optimism in discrimination, the bootstrap analysis produced an area under the receiver operating characteristic curve (AuROC) of 0.768 (95% CI 0.73-0.81), indicates a good ability and a significant level of agreement between the estimated and observed probabilities of risk (Supplementary material).

213

214 Simple score cut point identification

215 A very high sensitivity of 94.8% (95% CI 91.1-97.3) was observed at a cut point of \geq 4, while the specificity was 28.5% (95% CI 23.7-33.8). At a score of ≥10, the specificity was high at 216 217 91.7% (95% CI 88.2-94.5), but the sensitivity was lower at 44.3% (95% CI 37.8-51.0). The best cut point was determined by achieving a balance between sensitivity and specificity. For a score 218 219 of 6 or above, the sensitivity was 82.2% (95% CI 76.6-86.9), and the specificity was 55.2% (95% CI 49.6-60.7), with a likelihood ratio of positive result of 1.83 (95% CI 1.60-2.10). The positive 220 221 predictive value was 56.4% (95% CI 50.9-61.8), whereas the negative predictive value was 81.4% 222 (95% CI 75.7-86.3) (Table 4).

223

224 **Clinical utility**

In the context of triaging patients for osteopenia, the newly developed diagnostic prediction rule was applied. 32.37% (180 patients out of 556) were true negatives, this model can reduce the unnecessary BMD tests. Among the 211 patients who scored negatively (simple score below 6), 41 patients (18.55%) were false negatives for osteopenia, and only 2 patients (0.36%

of all patients) were diagnosed with osteoporosis. On the other hand, among those with a positive score test (simple score above 6), 146 patients had normal BMD and were recommended for follow-up, while 189 patients were confirmed to have osteopenia and received medical treatment according to the treatment guidelines.

233

234 **Discussion**

Despite the limitations, the current study managed to establish a diagnostic rule for predicting patients with osteopenia, which could strengthen an early diagnosis and the treatment of patients in osteopenia. This finding is highly relevant because our hospital faces a significant burden of bone density testing and a high prevalence of osteopenia. Moreover, the application of a predictive diagnosis logistic regression model, as conducted in the current study, also supports the efforts of other studies to implement more predictive analytics in clinical settings[20].

Our results emphasize the importance of a multi-factor approach in novel predictive model formulation. Specifically, our model uses the same age, sex, and weight as the known risk factors, established to predict osteopenia and osteoporosis, proven to be significant in other studies.[21] Similarly, the use of backward elimination for the purpose of precise identification of the factors allowed reducing the insignificant height and BMI from the model, as these variables have negligible impact on the model's predictability of outcomes in our patients.[22]

The calibration and discrimination results of our model are satisfactory and being confirmed. The results of the Hosmer-Lemeshow test and AuROC testify to the model's effective prediction of true osteopenia cases. This is confirmed by the literature on the appropriateness of calculating these metrics to check how well a diagnostic tool performs in clinical epidemiology and diagnostics.[23]

Furthermore, the use of this model demonstrated its significant clinical use. The prioritization of resources based on a simple score, which identifies high and low-risk patients, may also lower the risk of untreated osteopenia transitioning to osteoporosis and adhere to WHO, who suggests that more tests should be conducted on populations at higher risks.[24, 25]

Although the FRAX score is currently used in predicting the 10-year probability of hip fracture[26, 27], a study by Teeratakulpisarn et al[28]. reports that even though there is concordance between the 10-year probability of hip fractures for FRAX scores with and without BMD, this concordance declines in elderly and osteoporotic participants, and in those with FRAX scores without BMD. Therefore, to achieve higher accuracy, it is advisable to undergo BMD testing.

In 2001, Koh LK et al. [29] designed a simple tool to categorize postmenopausal Asian 262 women (OSTA score). They utilized a questionnaire to identify those in the cohort with 263 264 osteoporosis, defined as BMD T-scores \leq -2.5 and use multivariable logistic regression analysis. The tool had a good performance with an area under the ROC curve of 0.79. Subsequently, it 265 showed sensitivity of 91%, specificity of 45%, among others.[29] Additionally, upon a validation in 266 267 Thai population, OSTA score presented sensitivity of 51.7% and specificity of 77.4% with a false negative rate of ~20%.[30-33] The OSTA risk classification system showed that high and medium-268 risk patients were significantly more likely to sustain injuries in falls and have different femoral 269 270 bone fractures patterns compared to low-risk patients. Machine learning models particularly artificial neural networks offer another opportunity to predict low BMD. Comparison of both ANN 271 272 models to logistic regression models to predict low BMD had no significantly different in 273 performance for either the femoral neck or lumbar spine.[34] Although the OSTA score performs 274 well within the Thai population and particularly among postmenopausal women, however, it can 275 be limited use to the general population.

Our model's stability and reliability were internal validation via bootstrapping, process accounting for the potential optimism that can compromise prediction models developed in narrow or specific populations. All of these methods make our research more reliable and can be used to apply to similar settings with limited health care resources.

The study also has its limitations. In particular, the specificity of the model at some cut points was insufficient for real-life applications, resulting in overdiagnosis and overtreatment. This compromise between sensitivity and specificity is common in the development of diagnostic instruments, and it needs to be adjusted depending on the costs and risks of the disease. For future research, it is possible not only to include new, more prognostic factors but also to progress statistical instruments, such as machine learning. Further external validation is also required before adopting this model in other settings.

287

288 Conclusion

The development of a diagnostic prediction rule for osteopenia in a resource-limited context is a major progress in the field of bone health management. This instrument is likely to enhance patient prognosis and maximize the use of available healthcare resources by detecting and offering timely therapeutic treatment to those at risk.

293

294 Acknowledgement

295 This paper was supported by Suranaree University of Technology.

296

Funding 297 298 None 299 **Conflict of interest** 300 301 None 302 Author contribution statement 303 304 NK and TJ contributed to all parts of the research.PT, KP, and PT focused on discussing, reviewing, and editing the manuscript. 305 306 **Figure legends** 307 308 Figure 1: Study flow. 309 Figure 2: Calibration plot for model predicted risk for osteopenia versus actual risk. 310 Figure 3: Discrimination performance of the newly developed model, using clinical 311 characteristics to classify patients with normal and low bone mass density. Figure 4: Clinical utility. 312 313 **Tables** 314

- 315 **Table 1:** Baseline patient characteristics, underlying diseases, and laboratory investigations of
- the derivation cohort, along with a comparison of osteopenia cases and normal bone mineral
- 317 density tests (n = 556).

Patient characteristics	Osteopenia cases (n = 230)		Non-osteopenia cases (n = 326)		Univariable OR (95%CI)	p- value	AuROC
	n	(%)	n	(%)	, , , , , , , , , , , , , , , , , , ,		
Female gender	198	(86.09)	188	(57.67)	4.54 (2.94- 7.00)	< 0.001	0.64 (0.61-0.68)
Age, years (mean ± SD)	65.07	± 10.34	59.03	± 9.14	1.07 (1.05- 1.09)	< 0.001	0.68 (0.64-0.73)
Weight, kg (mean ± SD)	57.40	± 9.58	66.30	± 12.71	0.93 (0.91- 0.95)	< 0.001	0.29 (0.25-0.34)
Height, cm (mean ± SD)	155.22	± 7.50	160.53	± 8.03	0.92 (0.89- 0.94)	< 0.001	0.32 (0.28-0.37)
BMI, km/m ² (mean ± SD)	24.68	± 14.44	25.64	± 4.02	0.88 (0.84- 0.93)	< 0.001	0.37 (0.33-0.42)
Current smoking	1	(0.43)	5	(1.54)	0.28 (0.03- 2.40)	0.245	0.49 (0.49-0.50)
Early menopause	5	(2.17)	10	(3.09)	0.70 (0.24- 2.07)	0.516	0.50 (0.48-0.51)
Rheumatoid arthritis	1	(0.43)	2	(0.62)	0.70 (0.06- 7.80)	0.774	0.50 (0.49-0.51)
Diabetes mellitus	15	(6.52)	45	(13.89)	0.43 (0.23- 0.80)	0.007	0.46 (0.44-0.49)
Creatinine, g/dL (mean ± SD)	0.87	± 0.72	0.87	± 0.37	1.01 (0.72- 1.42)	0.967	0.42 (0.37-0.48)
eGFR, ml/min/1.73 m ² (mean ± SD)	68.59	± 24.13	83.71	± 25.39	0.97 (0.97- 0.98)	< 0.001	0.32 (0.28-0.37)
Chronic kidney disease	25	(10.92)	37	(11.46)	0.95 (0.55- 1.62)	0.844	0.50 (0.47-0.52)

Abbreviations: eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

Table 2: Full model multivariable logistic regression analysis.

Dradiatora		Full model				
Predictors	mOR	95% CI	P-value			
Female	5.33	3.03 - 9.38	0.000			
Age, year						
≤ 59	1					
60 – 69	3.59	2.25 - 5.74	< 0.001			
≥ 70	6.91	3.62 - 13.20	< 0.001			
Height, cm						
≥ 155	1					
< 155	0.97	0.57 - 1.64	0.903			
Weight, kg						

³¹⁹

	≥ 70	1		
	60 – 69	1.15	0.61 - 2.17	0.656
	50 – 59	1.66	0.72 - 3.82	0.233
	≤ 49	1.72	0.54 - 5.54	0.360
	Body mass index, kg/m ²			
	≥ 25.0	1		
	23.0 – 24.9	1.19	0.64 - 2.22	0.577
	18.5 – 22.9	1.71	0.79 - 3.69	0.169
	< 18.5	3.94	0.87 - 17.90	0.076
	Diabetes mellitus	0.35	0.17 - 0.71	0.004
	Estimated GFR			
	≥ 60	1		
	30 – 59	0.84	0.45 - 1.54	0.565
	15 – 29	1.89	0.22 - 16.05	0.558
	_ ≤ 14	1	Empty	
	Model intercept	.062		
321	Abbreviation: mOR, multivariable odds	ratio; BMI, I	body mass index; GFR	, glomerular filtration
323				
324				
325				
326				
327				
328				
329				

Predictors	mOR	95% CI	P-value	β Coefficient	Score
Female	4.09	2.51 - 6.68	0.000	1.41	4
Age, year					
≤ 59	1				
60 – 69	3.29	2.13 - 5.08	0.000	1.19	3.5
≥ 70	5.52	3.21 - 9.50	0.000	1.71	5
Weight, kg					
≥ 70	1				
60 – 69	1.40	0.80 - 2.45	0.240	0.34	1
50 – 59	2.60	1.51 - 4.50	0.001	0.96	3
≤ 49	3.96	2.02 - 7.76	0.000	1.38	4

Table 3: Reduced model with logit coefficients.

Model intercept	.065			
Abbreviation: mOR, mu	ultivariable odd	s ratio; BMI, body mas	s index	

332

331

- **Table 4:** Selection of score cut-off point with sensitivity, specificity, LHR+, PPV, NPV, and along
- 334 with 95% confidence interval.

	Score cut point	Sensitivity (%)	Specificity (%)	LHR+ (%)	PPV (%)	NPV (%)	
	≥ 4	94.8 (91.1-97.3)	28.5 (23.7-33.8)	1.33 (1.23-1.43)	48.3 (43.6-53.1)	88.6 (80.9-94.0)	
	≥ 6	82.2 (76.6-86.9)	55.2 (49.6-60.7)	1.83 (1.60-2.10)	56.4 (50.9-61.8)	81.4 (75.7-86.3)	
	≥ 10	44.3 (37.8-51.0)	91.7 (88.2-94.5)	5.35 (3.63-7.90)	79.1 (71.0-85.7)	70.0 (65.4-74.3)	
335	Abbreviation: LHR+, likelihood ratio for positive test; PPV, positive predictive value; NPV,						

336 negative predictive value

337

338

- 339
- - -
- 340
- 341

342

343 **References**

- Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Michalak M, Eder P, Dobrowolska A,
 et al. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with
 Inflammatory Bowel Disease. Nutrients. 2021;13(6). Epub 2021/06/03. doi:
- 10.3390/nu13061863. PubMed PMID: 34070791; PubMed Central PMCID: PMCPMC8227497.
- 348 2. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and
- treatment of osteoporosis. Postgrad Med J. 2007;83(982):509-17. Epub 2007/08/07. doi:
- 350 10.1136/pgmj.2007.057505. PubMed PMID: 17675543; PubMed Central PMCID:
- 351 PMCPMC2600106.
- 352 3. Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur J
- 353 Rheumatol. 2017;4(1):46-56. Epub 2017/03/16. doi: 10.5152/eurjrheum.2016.048. PubMed
- PMID: 28293453; PubMed Central PMCID: PMCPMC5335887.

355 Johnell O. Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005:16 4. Suppl 2:S3-7. Epub 2004/09/15. doi: 10.1007/s00198-004-1702-6. PubMed PMID: 15365697. 356 357 Tran T, Bliuc D, Pham HM, van Geel T, Adachi JD, Berger C, et al. A Risk Assessment 5. 358 Tool for Predicting Fragility Fractures and Mortality in the Elderly. J Bone Miner Res. 2020;35(10):1923-34. Epub 2020/05/28. doi: 10.1002/jbmr.4100. PubMed PMID: 32460361. 359 Rozental TD, Shah J, Chacko AT, Zurakowski D. Prevalence and predictors of 360 6. osteoporosis risk in orthopaedic patients. Clin Orthop Relat Res. 2010;468(7):1765-72. Epub 361 2009/11/17. doi: 10.1007/s11999-009-1162-6. PubMed PMID: 19911243; PubMed Central 362 363 PMCID: PMCPMC2881983. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 364 7. 2006;194(2 Suppl):S3-11. Epub 2006/02/02. doi: 10.1016/j.ajog.2005.08.047. PubMed PMID: 365 16448873. 366 Grams AE, Rehwald R, Bartsch A, Honold S, Freyschlag CF, Knoflach M, et al. 367 8. 368 Correlation between degenerative spine disease and bone marrow density: a retrospective investigation. BMC Med Imaging. 2016:16:17. Epub 2016/02/26. doi: 10.1186/s12880-016-369 0123-2. PubMed PMID: 26911278; PubMed Central PMCID: PMCPMC4765052. 370 371 9. Tang G, Feng L, Pei Y, Gu Z, Chen T, Feng Z. Low BMI, blood calcium and vitamin D, kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in 372 postmenopausal women. Front Endocrinol (Lausanne). 2023;14:1154927. Epub 2023/11/08. 373 374 doi: 10.3389/fendo.2023.1154927. PubMed PMID: 37937050; PubMed Central PMCID: 375 PMCPMC10627178. Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1 376 10. 377 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization 378 analysis. Osteoporos Int. 2023;34(6):1111-7. Epub 2023/04/04. doi: 10.1007/s00198-023-379 06734-6. PubMed PMID: 37012460. 380 11. Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. The pathophysiology of osteoporosis 381 in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of 382 increased bone marrow adiposity. Front Endocrinol (Lausanne). 2022;13:981487. Epub 383 2022/10/04. doi: 10.3389/fendo.2022.981487. PubMed PMID: 36187112; PubMed Central PMCID: PMCPMC9520254. 384 385 Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the 12. assessment, management and prevention of fragility fractures in patients with osteoporosis and 386 387 chronic kidney disease. Endocrine. 2021;73(3):509-29. Epub 2021/05/12. doi: 10.1007/s12020-021-02735-9. PubMed PMID: 33974225; PubMed Central PMCID: PMCPMC8325650. 388 Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q, et al. Development and validation of a risk 389 13. 390 prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a retrospective and multicenter study. BMC Geriatrics. 2023;23(1):698. doi: 10.1186/s12877-023-391 392 04306-1. Mauck KF, Cuddihy MT, Atkinson EJ, Melton LJ, 3rd. Use of clinical prediction rules in 393 14. 394 detecting osteoporosis in a population-based sample of postmenopausal women. Arch Intern 395 Med. 2005;165(5):530-6. Epub 2005/03/16. doi: 10.1001/archinte.165.5.530. PubMed PMID: 15767529. 396 Leeyaphan J, Rojjananukulpong K, Intarasompun P, Peerakul Y. Development and 397 15. 398 Validation of a New Clinical Diagnostic Screening Model for Osteoporosis in Postmenopausal 399 Women. J Bone Metab. 2023;30(2):179-88. Epub 2023/07/14. doi: 10.11005/jbm.2023.30.2.179. PubMed PMID: 37449350; PubMed Central PMCID: 400 401 PMCPMC10346005. Wang J, Kong C, Pan F, Lu S. Construction and Validation of a Nomogram Clinical 402 16. 403 Prediction Model for Predicting Osteoporosis in an Asymptomatic Elderly Population in Beijing. J Clin Med. 2023;12(4). Epub 2023/02/26. doi: 10.3390/jcm12041292. PubMed PMID: 36835828; 404 PubMed Central PMCID: PMCPMC9967366. 405

406 17. Aibar-Almazán A. Voltes-Martínez A. Castellote-Caballero Y. Afanador-Restrepo DF. Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of 407 408 Osteoporosis. Int J Mol Sci. 2022;23(16). Epub 2022/08/27. doi: 10.3390/ijms23169465. 409 PubMed PMID: 36012730; PubMed Central PMCID: PMCPMC9408932. Sun X, Chen Y, Gao Y, Zhang Z, Qin L, Song J, et al. Prediction Models for Osteoporotic 410 18. 411 Fractures Risk: A Systematic Review and Critical Appraisal. Aging Dis. 2022;13(4):1215-38. Epub 2022/07/21. doi: 10.14336/ad.2021.1206. PubMed PMID: 35855348; PubMed Central 412 413 PMCID: PMCPMC9286920. 414 19. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Jr., Moons KG, et al. Minimum sample 415 size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276-96. Epub 2018/10/26. doi: 10.1002/sim.7992. PubMed 416 PMID: 30357870; PubMed Central PMCID: PMCPMC6519266. 417 Riley RD, Pate A, Dhiman P, Archer L, Martin GP, Collins GS. Clinical prediction models 418 20. and the multiverse of madness. BMC Med. 2023;21(1):502. Epub 2023/12/19. doi: 419 10.1186/s12916-023-03212-y. PubMed PMID: 38110939; PubMed Central PMCID: 420 421 PMCPMC10729337. 422 21. Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview 423 on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. Epub 2018/11/23. doi: 10.2147/tcrm.S138000. PubMed PMID: 30464484; PubMed Central PMCID: 424 425 PMCPMC6225907. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical 426 22. 427 prediction modelling. Fam Med Community Health. 2020;8(1):e000262. Epub 2020/03/10. doi: 10.1136/fmch-2019-000262. PubMed PMID: 32148735; PubMed Central PMCID: 428 PMCPMC7032893. 429 430 23. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination 431 and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. Jama. 432 2017;318(14):1377-84. Epub 2017/10/20. doi: 10.1001/jama.2017.12126. PubMed PMID: 433 29049590. 434 Kanis JA. Assessment of fracture risk and its application to screening for 24. postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 435 1994;4(6):368-81. Epub 1994/11/01. doi: 10.1007/bf01622200. PubMed PMID: 7696835. 436 Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, et al. The risk-437 25. 438 stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective populationbased study. Design and baseline characteristics. Calcif Tissue Int. 2015;96(2):167-79. Epub 439 2015/01/13. doi: 10.1007/s00223-014-9950-8. PubMed PMID: 25578146. 440 441 26. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 442 443 2001;12(12):989-95. Epub 2002/02/16. doi: 10.1007/s001980170006. PubMed PMID: 11846333. 444 445 27. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International 446 Variations in Hip Fracture Probabilities: Implications for Risk Assessment. Journal of Bone and 447 Mineral Research. 2002;17(7):1237-44. doi: https://doi.org/10.1359/jbmr.2002.17.7.1237. Teeratakulpisarn N, Charoensri S, Theerakulpisut D, Pongchaiyakul C. FRAX score with 448 28. 449 and without bone mineral density: a comparison and factors affecting the discordance in osteoporosis treatment in Thais. Arch Osteoporos. 2021;16(1):44. Epub 2021/02/27. doi: 450 10.1007/s11657-021-00911-y. PubMed PMID: 33635451. 451 452 29. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699-705. 453 454 Epub 2001/10/03. doi: 10.1007/s001980170070. PubMed PMID: 11580084. Chaovisitsaree S, Namwongprom SN, Morakote N, Suntornlimsiri N, Piyamongkol W. 455 30. Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment in 456

- 457 Menopause Clinic, Chiang Mai. J Med Assoc Thai. 2007;90(3):420-5. Epub 2007/04/13.
 458 PubMed PMID: 17427514.
- 459 31. Geater S, Leelawattana R, Geater A. Validation of the OSTA index for discriminating
- between high and low probability of femoral neck and lumbar spine osteoporosis among Thai
 postmenopausal women. J Med Assoc Thai. 2004;87(11):1286-92. Epub 2005/04/14. PubMed
 PMID: 15825701.
- 463 32. Chen CC, Rau CS, Wu SC, Kuo PJ, Chen YC, Hsieh HY, et al. Association of
- 464 Osteoporosis Self-Assessment Tool for Asians (OSTA) Score with Clinical Presentation and
- 465 Expenditure in Hospitalized Trauma Patients with Femoral Fractures. Int J Environ Res Public
- 466 Health. 2016;13(10). Epub 2016/10/14. doi: 10.3390/ijerph13100995. PubMed PMID:
- 467 27735874; PubMed Central PMCID: PMCPMC5086734.
- 468 33. Panichyawat N, Tanmahasamut P. Comparison of OSTA index and KKOS scoring
- system for prediction of osteoporosis in postmenopausal women who attended Siriraj
- 470 Menopause Clinic. J Med Assoc Thai. 2012;95(11):1365-71. Epub 2012/12/21. PubMed PMID:
 471 23252200.
- 472 34. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro
- 473 R, et al. Prediction of low bone mineral density in postmenopausal women by artificial neural
- 474 network model compared to logistic regression model. J Med Assoc Thai. 1997;80(8):508-15.
- 475 Epub 1997/08/01. PubMed PMID: 9277083.
- 476







